Wall Street’s biggest hedge funds dumped chunks of their “Magnificent Seven” tech holdings during the third quarter of 2025, cutting down positions in Nvidia, Amazon, Alphabet, and Meta as shown in new regulatory filings published Friday. The pullback came just as markets were gaining steam, with the S&P 500 up nearly 8% and the Nasdaq […]Wall Street’s biggest hedge funds dumped chunks of their “Magnificent Seven” tech holdings during the third quarter of 2025, cutting down positions in Nvidia, Amazon, Alphabet, and Meta as shown in new regulatory filings published Friday. The pullback came just as markets were gaining steam, with the S&P 500 up nearly 8% and the Nasdaq […]

Wall Street’s hedge funds cut positions in Nvidia, Amazon, Alphabet, Meta in Q3

Wall Street’s biggest hedge funds dumped chunks of their “Magnificent Seven” tech holdings during the third quarter of 2025, cutting down positions in Nvidia, Amazon, Alphabet, and Meta as shown in new regulatory filings published Friday.

The pullback came just as markets were gaining steam, with the S&P 500 up nearly 8% and the Nasdaq 100 climbing around 9%, fueled in part by falling bond yields after expectations of rate cuts pushed 10-year Treasury yields down about seven basis points.

The data came from mandatory 13‑F filings, and the reports tracked investment changes through September 30.

The latest trades showed how aggressive some of the largest money managers were in reducing risk in Big Tech. It wasn’t just the names people watch on CNBC every day, hedge funds also trimmed bets in healthcare and energy names.

That move followed a second quarter that saw firms piling into artificial intelligence plays. But once the AI frenzy cooled, and inflated valuations began dropping, managers pulled back hard and redirected capital into sectors like application software, e‑commerce, and payments.

Bridgewater dumps Nvidia, loads up on payments before Fiserv tanks

Ray Dalio’s Bridgewater Associates, which outperformed many peers during the first nine months of 2025, chopped its Nvidia stake by nearly two-thirds, ending Q3 with 2.5 million shares, and halved its position in Alphabet, now down to 2.65 million shares.

At the same time, Bridgewater raised stakes in Adobe, Dynatrace, and Etsy, all tied to software and online platforms, and increased its holding in payments firm Fiserv before it reported weak earnings and slashed revenue guidance for the second quarter in a row. The result? Fiserv’s market cap cratered by about $30 billion in one day.

Discovery Capital, founded by Rob Citrone, entered the same Fiserv trade before the nosedive, and also opened fresh positions in Alphabet, Cigna, Elevance Health, and Cleveland-Cliffs, a steel company.

Meanwhile, Lone Pine Capital cut its Meta stake by 34.8%, while Tiger Global did it even harder, slashing 62.6% of its holding in the same company.

Coatue and Balyasny shuffle AI and iPhone bets, Buffett tweaks Alphabet and Apple

Philippe Laffont’s Coatue Management dialed down its Nvidia exposure by 14.1%, dropping the position to 9.9 million shares, still big, but no longer as aggressive.

Coatue’s reduction lined up with similar moves from Bridgewater and Michael Burry’s Scion Asset Management, who also backed away from Nvidia during the quarter.

Dmitry Balyasny’s Balyasny Asset Management went the other way on Apple, multiplying its holding several times over during the same quarter.

And over at Berkshire Hathaway, Warren Buffett’s team reported a brand-new $4.3 billion stake in Alphabet, even as it continued to trim down its Apple position. This was the last equity portfolio disclosure before Buffett hands over CEO duties.

These trades didn’t say anything about short positions or current holdings, 13‑Fs never do, but they painted a clear picture of where money was being moved and when. The filings showed a lot more than just portfolio tinkering.

The biggest hedge funds on Wall Street were stepping away from the most hyped tech names of the year and diving into new sectors.

Every one of these decisions came with real numbers, real stakes, and real consequences, and by the end of the third quarter, the tech party had fewer guests.

Get seen where it counts. Advertise in Cryptopolitan Research and reach crypto’s sharpest investors and builders.

Market Opportunity
PoP Planet Logo
PoP Planet Price(P)
$0.01511
$0.01511$0.01511
0.00%
USD
PoP Planet (P) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23